American Journal of Drug Delivery and Therapeutics Open Access

  • ISSN: 2349-7211
  • Journal h-index: 6
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Krithika Rajagopalan

Krithika Rajagopalan
Vice President & Head
Global HEOR Pricing & Market Access & US Health Economics & Outcomes Research, USA


Kitty (Krithika) Rajagopalan, B.S (Pharm), MS, PhD is a visionary leader with over 23 years of operational experience in building and leading Global & US Health Economics, Pricing, Policy and Market Access function across drugs, devices, and biologics? industry. Her cross-therapeutic area Health Economics & Outcomes Research (HEOR) leadership expertise spans a wide spectrum of diseases and conditions including but not limited to psychiatry, neurology, oncology, cardio-pulmonary, respiratory, auto-immune and other rare diseases. She owns multiple copyrights for patient reported outcomes instruments and has published over 80+ manuscripts in peer-reviewed journals. She also has presented over 600 scientific papers at meetings and is an invited speaker at DIA, ISPOR and other forums on health care topics as diverse as global reimbursement, HEOR methodologies, Patient Reported Outcomes in Clinical trials, public policy issues with the emergence of ACOs and expanded role of HEOR. Her global experience also includes successful interactions and negotiations with FDA, EMA (Global Healthcare Regulatory) and payor (US and Ex-US) bodies in securing PRO label claims, and successful market access through the development of credible scientific evidence to support reimbursement guidance and health care decision-making. Kitty?s global geographic experience span includes US, Canada, Australia, Europe (including UK), Latin America and Asia, with specific emphasis on BRIC (Brazil, Russia, India, and China) Nations. Some of her notable successes include: First in class QoL and PRO label claims; Medicare ?New technology/pass-through reimbursement?; Positive reimbursement guidance from NICE, PBAC, other HTA bodies and US Public/Private payors and enabling device-related reimbursement legislation changes in Brazil.